Hong Kong-listed Guanze Medical (02427) released its audited results for the year ended 31 December 2025, moving from profit to loss on sharply lower sales of medical imaging products and services.
Key Financials • Revenue: RMB88.45 million, down 43.20% year-on-year (2024: RMB155.74 million). • Net loss: RMB29.96 million versus net profit of RMB17.45 million in 2024. • Basic and diluted loss per share: RMB0.03 (2024: earnings of RMB0.02). • Gross profit: RMB22.13 million, contracting 64.77%; gross margin fell to 25.02% from 40.31%. • Operating loss before tax: RMB31.38 million (2024: profit of RMB26.31 million). • Income tax credit: RMB1.42 million (2024: tax expense of RMB8.86 million). • Cash and cash equivalents: RMB21.93 million, down RMB6.29 million from end-2024. • Interest-bearing bank borrowings: RMB12.76 million, reduced from RMB17.71 million; gearing ratio eased to 5.5% (2024: 6.8%). • Net current assets: RMB175.21 million (2024: RMB201.98 million). • No dividend declared for 2025.
Revenue Breakdown • Medical imaging film products: RMB75.52 million, a decline of 35.99%. • Medical imaging cloud services: RMB2.20 million, down 76.07%. • Software sales: RMB10.73 million, down 62.35%. Film products contributed 85% of revenue, cloud services 3%, and software 12%.
Cost and Expenses • Cost of sales: RMB66.32 million, down 28.65% on lower film volumes and pricing. • Selling & distribution expenses rose 12.34% to RMB20.01 million, reflecting higher channel and depreciation costs. • Administrative expenses edged up 3.36% to RMB14.21 million. • Research & development spending increased 42.30% to RMB5.79 million. • One-off impairment charges: RMB5.07 million on property, plant & equipment and RMB3.83 million on trade receivables. • Other expenses jumped to RMB10.23 million, mainly from a RMB10.23 million loss on disposal of assets.
Balance Sheet Highlights • Total assets: RMB270.69 million; equity: RMB232.28 million. • Inventories declined 48.75% to RMB7.37 million. • Trade and bills receivables decreased 6.27% to RMB163.29 million; top five customers accounted for 80.7% of trade receivables. • Property, plant & equipment stood at RMB44.72 million after impairments. • Pledged assets of RMB8.09 million secure RMB7.50 million of borrowings.
Operational Developments • Full-year film shipment volume fell 30.5% to 11.6 million units amid price pressure and market expansion at lower prices. • Cloud services revenue contracted in tandem with lower film sales. • High & New Technology Enterprise status granted a 15% concessionary tax rate. • Net cash from operations totaled RMB10.44 million; capex and related prepayments consumed RMB11.32 million.
Strategic and Corporate Updates • Management prioritises expansion within Shandong Province, enhancement of cloud services and product diversification. • Undrawn bank facilities of RMB3.20 million remain available. • Net IPO proceeds utilisation reached RMB48.20 million; RMB20.40 million earmarked mainly for potential acquisitions and cloud service enhancement is expected to be spent by end-2027. • Change of control completed on 6 February 2026: FUNDE (Hong Kong) Investment Holdings acquired a 73.6% stake from Meng A Capital, making Mr. Cheung Chun the new ultimate controlling shareholder.
Outlook Industry reports cited by the company highlight continued growth in China’s medical device and imaging cloud markets, driven by ageing demographics, chronic disease prevalence and national initiatives for data sharing and AI-assisted diagnostics. Management plans to leverage PACS and cloud capabilities to align with forthcoming nationwide medical-imaging cloud infrastructure.
No material acquisitions, disposals or contingent liabilities were recorded during the period.
Comments